Table 1.
Baseline characteristics.
| Median Age, Years (Range) | |
| 54 (34–70) | |
| Immunophenotype (%) | |
| HER2-positive | 20 (51) |
| Luminal B | 12 (31) |
| Triple negative | 7 (18) |
| Diagnosis-specific graded prognostic assessment (%) | |
| 0–1 | 1 (2.5) |
| 1.5–2 | 6 (15.5) |
| 2.5–3 | 6 (15.5) |
| 3.5–4 | 26 (66.5) |
| Extracranial metastases status (%) | |
| Absent | 6 (15.5) |
| Progressive | 17 (43.5) |
| Stable | 16 (41) |
| Previous treatment to the brain (%) | |
| None | 18 (46) |
| SRT | 9 (23) |
| Surgery | 5 (13) |
| WBRT | 4 (10) |
| Surgery and SRT or WBRT | 3 (8) |
| Systemic therapy before CTC1 (%) | |
| None | 3 (8) |
| Hormonal therapy | 9 (23) |
| Chemotherapy | 12 (31) |
| HER2-targeted therapy | 15 (38) |